Oncolytic Vaccinia Virus Carrying Aphrocallistes vastus Lectin (oncoVV-AVL) Enhances Inflammatory Response in Hepatocellular Carcinoma Cells

Mar Drugs. 2022 Oct 26;20(11):667. doi: 10.3390/md20110667.

Abstract

Aphrocallistes vastus lectin (AVL) is a C-type marine lectin derived from sponges. Our previous study demonstrated that oncolytic vaccinia virus carrying AVL (oncoVV-AVL) significantly enhanced the cytotoxicity of oncoVV in cervical cancer, colorectal cancer and hepatocellular carcinoma through the activation of Ras/ERK, MAPK/ERK and PI3K/Akt signaling pathways. In this study, the inflammatory response induced by oncoVV-AVL in a hepatocellular carcinoma cell (HCC) model was investigated. The results showed that oncoVV-AVL increased the levels of inflammatory cytokines including IL-6, IL-8 and TNF-α through activating the AP-1 signaling pathway in HCC. This study provides novel insights into the utilization of lectin AVL in the field of cancer therapy.

Keywords: AP-1; Aphrocallistes vastus lectin; hepatocellular carcinoma; oncolytic vaccinia virus.

MeSH terms

  • Animals
  • Carcinoma, Hepatocellular* / drug therapy
  • Carcinoma, Hepatocellular* / metabolism
  • Cell Line, Tumor
  • Humans
  • Lectins / pharmacology
  • Liver Neoplasms* / drug therapy
  • Liver Neoplasms* / metabolism
  • Oncolytic Virotherapy* / methods
  • Oncolytic Viruses*
  • Phosphatidylinositol 3-Kinases
  • Porifera*
  • Vaccinia virus

Substances

  • Lectins
  • Phosphatidylinositol 3-Kinases